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Fatigue is an important contributor to poor quality of life. The aim of our research was to identify factors associated with fatigue
among patients with Parkinson’s disease (PD). The sample consisted of 150 patients. The Multidimensional Fatigue Inventory (MFI),
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS), Hospital Anxiety and Depression Scale (HADS) and Charlson co-morbidity index
were used for analysis. Demographic data were obtained in a structured interview. T-test, w2-test and general linear regression were used.
Fatigue was reported in 81% of the patients, with the worst scores in physical fatigue. Mood disorders and worse UPDRS scores were
associated with fatigue.
r 2007 Elsevier Ltd. All rights reserved.
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Fatigue is a frequent complaint of patients with
Parkinson’s disease (PD) with up to 40–56% of patients
reporting it during the course of their disease [1–4], of
whom 15–33% describe it as the most disabling symptom
[5]. Like other non-motor problems, fatigue is often an
under-appreciated and neglected symptom, despite the fact
that it may even precede the appearance of cardinal motor
signs [6]. Fatigue may be present as a transient or persistent
feature of PD [7]. Fatigue is also an important contributor
to poor quality of life in PD and it is connected to worse
physical and mental health [8,9].
Fatigue is a subjective experience. Although lacking a
standard deﬁnition, fatigue can be deﬁned as a state of
extreme tiredness, weakness, lack of energy, i.e., exhaus-
tion, (physical, mental, or both) [10]. Physical fatigue in PD
patients is reported after inadequate sleep or rest, or aftere front matter r 2007 Elsevier Ltd. All rights reserved.
rkreldis.2007.07.017
ing author. Tel.: +421 911128314; fax: +421 557898546.
ess: eva.havlikova@upjs.sk (E. Havlikova).physical exertion, and may be associated with physical
condition, or decline in strength generation or decline in
speed of repetitive movements due to parkinsonism.
Mental fatigue is reported after mental effort or when
patients lack the motivation to initiate activities, and may
result from sleep disturbances, slowed mental processes, or
depression [11].
Fatigue has been described in various chronic diseases,
neurological and non-neurological. It is reported to be the
major problem in multiple sclerosis patients, 55–79% of
them suffer from fatigue [12,13], up to 42–80% of patients
with rheumatoid arthritis [14], and 57% of patients with
primary Sjo¨gren’s syndrome [15]. Several studies have been
performed to identify correlates of fatigue in chronic
disorders. Associations between fatigue, disease severity or
disease activity have been found and so are associations
between fatigue and depression or sleep disorders, but not
with age or disease duration [12,13,15].
In recent years, fatigue has become an important
research variable and several studies have highlighted its
clinical signiﬁcance in PD. While more is known about its
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Table 1
Clinical variables of Parkinson’s disease patients (N ¼ 150)
Variable %, mean7S.D.
1. UPRDS 36.9720.9
Male (n ¼ 77) 38.8721.1







4. Charlson index 3.971.8






6. Antiparkinsonian drugs used
L-dopa 18 (12%)
Dopamine agonists 36 (24%)
L-dopa+COMT inhibitors 38 (25.3%)
L-dopa+dopamine agonists 20 (13.3%)
L-dopa+COMT inhibitor+dopamine agonists 16 (10.7%)
Other 22 (14.7%)
UPDRS, Uniﬁed Parkinson’s Disease Rating Scale; MFI, multidimen-
sional fatigue inventory.
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progress has been made so far in understanding its etiology
and pathogenesis. Biological [16], clinical and psychosocial
variables may play a role [7,11]. As yet, there are few
ﬁndings suggesting how to manage the problem clinically.
One possible way is the recognition and proper manage-
ment of factors leading to occurrence of fatigue.
PD is a disorder particularly affecting more elderly
patients. This population suffers from a higher incidence of
cardiovascular, neurovascular disorders, diseases of bones
and joints [17,18], and these conditions also require more
frequent hospital admissions [18]. As these disorders are
often associated with patients’ complaints of fatigue
[14,15,19], it is possible that the presence of these
accompanying problems may lead to fatigue or may
increase feelings of fatigue. As this disease mainly worsens
patients’ functional status (through worsening of move-
ment abilities or through a feeling of pain), we expect co-
morbidities to inﬂuence the physical dimensions of fatigue.
So far the variables predicting fatigue in PD have not
been clariﬁed. The aim of this study is to identify some
clinical and psychosocial factors associated with the
occurrence of fatigue in PD patients.
2. Methods
2.1. Patients
This cross-sectional study evaluated fatigue in a study population of
150 patients with PD. The patients were recruited from the hospitals and
outpatients departments in the East Slovakian region between February
2004 and November 2005, based on medical records. All patients were
diagnosed according to the United Kingdom Parkinson’s Disease Society
Brain Clinical Criteria [20] and their mental abilities were assessed with the
Mini-Mental State Exam (MMSE) [21]. The sample included patients with
idiopathic PD. Exclusion criteria were deﬁned as follows: (1) MMSE lower
than 24, (2) disease duration longer than 15 years and (3) co-morbidities
associated with fatigue.
The study was approved by the local Ethical Committee. Informed
consent was obtained from each patient.
2.2. Data collection
All participating patients received a mailed questionnaire accompanied
by a written informed consent form. After 3 weeks, all patients were
interviewed on relevant issues that were no part of the questionnaire. After
this structured interview, a neurologist assessed the patient’s disease
severity with the Uniﬁed Parkinson’s Disease Rating Scale (UPDRS
Version 3.0; [22]), including Hoehn and Yahr staging [23] and the Schwab
and England disability scale [24]. Patients who were unable to ﬁll in the
questionnaire because of tremor, motor impairment of their hand or visual
problems answered the questions during an oral interview.
2.3. Sample description
A total of 150 patients (77 men (51.3%), 73 women (48.7%)) completed
the questionnaire and the interview, followed by examination by the
neurologist. The mean age of the patients was 68.478.8 years (range
44–83 years): 69.178.6 men and 67.778.9 women. Mean age at disease
onset was 61.5711.1 years. Mean disease duration was 7.977.9 years:
7.0975.4 for the male population and 8.979.8 for women. These genderdifferences were statistically not signiﬁcant. Details of the clinical proﬁle
and variables of the patients are shown in Table 1.
3. Measures
3.1. Multidimensional fatigue inventory (MFI)
Fatigue was assessed with the MFI as the primary
outcome measure in PD patients. The MFI is a 20-item
self-report instrument designed and validated by Smets et
al. [25]. It measures ﬁve dimensions of fatigue: general
fatigue, physical fatigue, mental fatigue, reduced motiva-
tion, and reduced activity. There are four items in each
dimension. The score on each item ranges from 1 (no
fatigue) to 5 (very fatigued). The score in each dimension
ranges from 4 (no fatigue) to 20 (highest possible fatigue).
This instrument is a frequently used fatigue questionnaire
in Europe, repeatedly used in patients with neurological
diseases [11]. It has been successfully applied in several
clinical groups. In the present research, the instrument was
found to have good internal consistency with Cronbach’s
alpha coefﬁcient of 0.84.
3.2. Hospital Anxiety and Depression Scale (HADS)
Anxiety and depression were assessed using the HADS.
This self-administered scale simultaneously evaluates anxi-
ety (HADS-A) and depression (HADS-D). It consists of 14
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assessment of depression) scoring from 0 (no problem) to 3
(extreme problem). The cut-off values were applied in
order to determine the proportion of patients considered
unimpaired (not anxious or not depressed, scoring p7 on
each subscale), possibly impaired (8–10 on each subscale),
or probably impaired (X11 on each subscale) [26]. In the
present study, Cronbach’s alpha was 0.82 for the anxiety
domain and 0.79 for the depression domain.
3.3. The Unified Parkinson’s Disease Rating Scale
(UPDRS)
The UPDRS is a four-subscale measure (mental state,
activities of daily living, motor examination, and complica-
tions). Two further instruments are attached to the
UPDRS, namely: (1) a modiﬁed Hoehn and Yahr Staging
and (2) the Schwab and England Scale. Ratings are
observation based, and scores are obtained by interview
and physical examination. As a consequence of its design,
the UPDRS allows for partial and total scores [22–24].
3.4. Co-morbidities
The Charlson index was used to evaluate the presence of
co-morbidities. It consists of 19 conditions (some of them
representing two degrees of severity of the same condition)
with values of 1–6, based on the adjusted risk of 1-year
mortality. The overall co-morbidity score reﬂects the
cumulative increased likelihood of 1-year mortality. It
has been combined with age to form an age–co-morbidity
index [27,28]. Two independent researchers assessed co-
morbidities on the basis of patients’ questionnaires.
Differences were resolved through discussion with refer-
ence to a third reviewer, if necessary.
3.5. Personal characteristics
Age, gender, disease duration and educational level of
the patient were based on the Neurology Department
registry information and conﬁrmed at the time of inter-
view. Gender (0 ¼ male and 1 ¼ female) and educational
level were used in the regression analysis as covariates with
the level of education coded as: 1—basic (primary
education or for secondary education without school
leaving examination), 2—middle (secondary education
with school leaving examination) and 3—higher (college
or university degrees).
4. Statistical analysis
Discrete variables were compared with the w2-test and
are presented as percentages. Continuous variables were
compared with the Student t-test and are presented as
mean7S.D. p-Values o0.05 were considered statistically
signiﬁcant. Based on the conceptual model, a series of
regression were established to provide the coefﬁcients toexamine the relative strength of disease duration, Charlson
index, anxiety, depression and UPDRS, Hoehn and Yahr
staging, and Schwab and England scores on ﬁve domains
of fatigue: general fatigue, physical fatigue, reduced
activity, reduced motivation and mental fatigue.
The coefﬁcients provided are standardized regression
coefﬁcients (beta) that identify the net effects (i.e.,
controlling for other covariates) of each variable on the
respective outcome. The regression analysis also provides
basic goodness-of-ﬁt information (R2 and p-values) for the
respective equations.
Statistical analyses were performed using the statistical
software program SPSS 12.0 for Windows.
5. Results
Out of 497 patients with PD meeting the inclusion
criteria: 41 did not wish to participate in the study and 284
did not respond to the invitation. Total response rate was
30.2%. Out of those who agreed to participate, 11 patients
were excluded because of the exclusion criteria, 11 patients
were not included because of missing data (these patients
agreed to participate in the study, ﬁlled in the ques-
tionnaire, but refused to come for the oral interview), and
150 remained for analysis. Non-responders did not differ
signiﬁcantly from the analyzed group in age (mean
difference, 1.9 years, S.E. ¼ 0.78; t ¼ 1.965; 95% CI
0.46–3.54). However, males were overrepresented in the
study sample, difference 8.1%, S.E. ¼ 0.049; 95% CI
0.015–17.6 (difference of proportions test) [29].
Looking ﬁrst at the disease-related factors, co-morbidity
and disease duration were not signiﬁcant for any of the ﬁve
fatigue outcomes. However, the UPDRS had signiﬁcant
effects on all domains of fatigue, as well as depression.
Depression (beta ¼ 0.55) had the strongest association
with reduced motivation. Both depression and UPDRS
were signiﬁcantly related to higher levels of reduced
motivation (beta ¼ 0.55), but anxiety was related to lower
levels of motivation (Table 2).
Depression also had an important relation to general
fatigue, physical fatigue, activity and mental fatigue
(beta ¼ 0.34, 0.31, 0.34 and 0.29, respectively). Impor-
tantly, these relationships persisted when the effects of
gender and educational level were statistically controlled.
The proposed models explained 34% of the variance in
general fatigue, 36% of the variance in physical fatigue,
38% in activity, 35% in motivation and 34% in mental
fatigue.
6. Discussion
Fatigue is considered to be a part of normal aging [30],
but the high prevalence of fatigue in PD patients cannot be
explained only by the advanced age of these patients. Our
study moreover shows fatigue as not being related to
gender and age. This corresponds with the ﬁndings of
studies in other chronic disorders, where age as well as
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Table 2
General linear model: associations of Clinical and Psychological factors with each of the ﬁve domains of MFI (controlled for age, gender and education
level)
Variables General fatigue Physical fatigue Reduced activity Reduced motivation Mental fatigue
Beta p Beta p Beta p Beta p Beta p
Disease-related
Disease duration 0.03 0.419 0.03 0.339 0.02 0.543 0.02 0.522 0.03 0.474
Charlson index 0.20 0.473 0.17 0.497 0.21 0.405 0.06 0.825 0.04 0.872
UPDRS 0.07 0.000 0.08 0.000 0.09 0.000 0.04 0.002 0.08 0.000
Psychological distress
Anxiety 0.16 0.049 0.02 0.822 0.14 0.067 0.17 0.029 0.02 0.777
Depression 0.34 0.000 0.31 0.000 0.34 0.000 0.55 0.000 0.29 0.000
R ¼ 0.58 R ¼ 0.60 R ¼ 0.61 R ¼ 0.59 R ¼ 0.59
R2 ¼ 0.34 R2 ¼ 0.36 R2 ¼ 0.38 R2 ¼ 0.35 R2 ¼ 0.34
Adjusted R2 ¼ 0.29 Adjusted R2 ¼ 0.32 Adjusted R2 ¼ 0.34 Adjusted R2 ¼ 0.30 Adjusted R2 ¼ 0.30
po0.000 po0.000 po0.000 po0.000 po0.000
R2: explained variance.
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affect much younger populations [11,13,31]. Similarly, the
level of education proved not to be associated with fatigue.
Existing studies on PD patients and other progressive
disorders also failed to show signiﬁcant relationship
between fatigue and disease duration [7,12,15].
Nearly 50% of PD patients report the presence of at
least one co-morbidity [18]. Based on the ﬁndings of the
high prevalence of fatigue in cerebrovascular diseases [19]
and diseases of joints and bones [14,15], we expected that
these accompanying problems might affect patients’ levels
of fatigue. Co-morbidities were reported by 47% of our
sample, especially vascular events (35%) and joints diseases
(12%). For all the ﬁve domains, however, co-morbidities
did not appear to be signiﬁcant. The explanation of this
observed non-signiﬁcant relationship is not clear at this
moment, and further studies should be performed in
future.
Depression was signiﬁcantly related to each of the ﬁve
fatigue domains. It was identiﬁed in 14% of our sample,
which is less prevalent than was documented in previous
studies [1,32]. A higher level of depression is associated
with a higher level of fatigue. This relationship was the
strongest for reduced motivation and reduced activity,
weaker for general and physical fatigue and the weakest for
mental fatigue. These ﬁndings are partly similar to the
ﬁndings of Lou et al. [11]; in a sample of 39 PD patients,
depression was related to mental dimensions of fatigue
(mental fatigue), but not with physical fatigue. The
association between depression and fatigue is still con-
troversial because of the possible overlap in symptomatol-
ogy between PD and major depression: fatigue and
sleep problems are among the diagnostic criteria for
both. Leentjens et al. [33] in their study proposed the
use of an adjusted cut-off score 18/19 for better discrimina-
tion between depressed and non-depressed PD patients;
however, as the sample size was small relative to thenumber of items, this ﬁnding should be viewed with some
caution.
The term anxiety is used to denote an intermittent or
sustained emotional state characterized by subjective
feelings of nervousness, irritability, uneasy anticipation
and apprehension [34]. Anxiety signs usually accompany
depression. Anxiety was reported in 30.6% of our sample.
We found anxiety to be connected with reduced motivation
and general fatigue. Although we found a correlation
between anxiety and mental fatigue, in the multiple linear
regression model anxiety did not prove to be associated
with mental fatigue dimensions. Anxiety also has an
overlap in symptomatology with fatigue, as has depression;
increased muscular tension, giddiness, trembling and
sweating are among the diagnostic criteria for anxiety
disorder [34].
Patients scored higher in the physical fatigue domain. A
possible explanation is that PD affects more physical
abilities (stiffness, slow movements, tremor), although non-
motor problems (depression, anxiety, sleep difﬁculties,
sensory symptoms) are also frequent and disabling [1].
We found functional status to have a signiﬁcant
relationship with all ﬁve fatigue domains, strongest for
the physical fatigue and weakest for the reduced motiva-
tion domain. The physical component of fatigue appears to
be associated with worse functional status as patients may
have less muscle strength and less energy supply. Garber
and Friedman [5] evaluated fatigue, physical activity and
physical function in a non-random sample of 37 PD
patients, and they found that patients with more severe
fatigue had poorer physical function compared with
patients with less fatigue. Our ﬁndings on the relation
between functional status and all the MFI components are
in contrast with the study of Karlsen et al. [3], who found
no relationship in a sample of 233 PD patients between
disease severity measured by UPDRS and fatigue. How-
ever, in their study fatigue was measured not with a
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Health Proﬁle; fatigue was considered as a manifestation
of the energy domain. The ﬁndings of the study of Lou et
al. [11] in a sample of 39 PD patients also do not
correspond with our results. In their study, disease severity
measured by Hoehn and Yahr did not correlate with any of
the dimensions in the MFI.
There were limitations to the present research. Our
sample consisted mostly of patients who were able to come
for the examination and interview—either alone or with a
family member as a companion. So we suppose that non-
responders were patients with worse functional status,
mostly bedridden. Despite the rather low response rate, in
this selected population fatigue is already a serious
problem, so we expect this to be even worse in the total
PD patients group.
This is the ﬁrst time, to our knowledge, that factors
related to the separate components of fatigue have been
studied. Previous studies showed an association of depres-
sion with the mental dimensions of fatigue, but we have
discovered in our study that depression has an important
relationship not only with the mental dimensions of
fatigue, but with the physical dimensions as well. Further
studies focusing on behavioral and psychosocial factors
should be performed in future, cross-sectional as well as
longitudinal, to better understand this problem and to
explore the role of these factors leading to fatigue
over time.
Neurologists frequently fail to recognize fatigue. General
problems in assessing fatigue are its subjective nature, and
in PD particularly the high prevalence of other non-motor
symptoms that may overlap. The new onset of fatigue in an
older individual may be connected to the development of a
somatic or psychiatric disease. We suggest that the elevated
levels of fatigue in PD patients deserve special attention, to
develop strategies to relieve this complaint. As PD is a
progressive disorder, in clinical practice neurologists often
challenge the worsening of functional status, even in cases
of optimal treatment with antiparkinsonian drugs. This is
why we stress the importance of identifying other possible
treatable disorders leading to fatigue. Treatment of
depression may lead to improvement in both mental and
physical dimensions of fatigue.Acknowledgment
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